Literature DB >> 32822001

Rhoj Is a Novel Target for Progression and Invasion of Glioblastoma by Impairing Cytoskeleton Dynamics.

Mei Wang1,2, Xiaochun Jiang3, Yongbo Yang4, Hongjin Chen2, Chengfei Zhang2, Haojun Xu2, Bin Qi5, Chengyun Yao6, Hongping Xia7,8,9,10.   

Abstract

Rho GTPase family members were identified as critical regulators of cell morphology, actin cytoskeleton organization, cell movement, and cell cycle and also contributed to tumor progression, which have been implicated in various types of cancer metastasis and growth. Here, we firstly reported the dysregulation of Rhoj in glioblastoma multiforme (GBM) and aimed to investigate the role and mechanism of Rhoj in GBM. We analyzed the expression of 21 Rho GTPases family members and validated the expression of Rhoj in GBM by immunohistochemistry. We further investigated the role and mechanism of Rhoj in GBM both in vitro and in vivo. We observed that Rhoj is significantly overexpressed in GBM and associated with patients' survival. However, the role and underlying molecular mechanism of Rhoj in GBM are still unclear. We demonstrated that transcription factor c-Jun regulated the expression of Rhoj, and Rhoj interacted with moesin to promote GBM cell proliferation and migration by potentiating the activation of Rac1/PAK pathway and cytoskeletal dynamics. Rhoj may promote migration and invasion of GBM cells by regulating epithelial-mesenchymal transition (EMT)-like process. In conclusion, the Rhoj/Rac1/PAK signaling mediates invasion and progression of GBM and is a potential therapeutic target for GBM treatment. Rhoj may also be a promising biomarker for GBM diagnosis and prognosis.

Entities:  

Keywords:  GBM; Rhoj; actin cytoskeleton; invasion; moesin

Year:  2020        PMID: 32822001      PMCID: PMC7851251          DOI: 10.1007/s13311-020-00910-w

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  25 in total

1.  Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain.

Authors:  M A Pearson; D Reczek; A Bretscher; P A Karplus
Journal:  Cell       Date:  2000-04-28       Impact factor: 41.582

Review 2.  Paving the Rho in cancer metastasis: Rho GTPases and beyond.

Authors:  Sepp Jansen; Reinoud Gosens; Thomas Wieland; Martina Schmidt
Journal:  Pharmacol Ther       Date:  2017-09-11       Impact factor: 12.310

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

4.  Role of glutamine synthetase in angiogenesis beyond glutamine synthesis.

Authors:  Guy Eelen; Charlotte Dubois; Anna Rita Cantelmo; Jermaine Goveia; Ulrike Brüning; Michael DeRan; Gopala Jarugumilli; Jos van Rijssel; Giorgio Saladino; Federico Comitani; Annalisa Zecchin; Susana Rocha; Rongyuan Chen; Hongling Huang; Saar Vandekeere; Joanna Kalucka; Christian Lange; Francisco Morales-Rodriguez; Bert Cruys; Lucas Treps; Leanne Ramer; Stefan Vinckier; Katleen Brepoels; Sabine Wyns; Joris Souffreau; Luc Schoonjans; Wouter H Lamers; Yi Wu; Jurgen Haustraete; Johan Hofkens; Sandra Liekens; Richard Cubbon; Bart Ghesquière; Mieke Dewerchin; Francesco L Gervasio; Xuri Li; Jaap D van Buul; Xu Wu; Peter Carmeliet
Journal:  Nature       Date:  2018-08-29       Impact factor: 49.962

5.  The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling.

Authors:  Tomoyo Okada; Surajit Sinha; Ilaria Esposito; Gaia Schiavon; Miguel A López-Lago; Wenjing Su; Christine A Pratilas; Cristina Abele; Jonathan M Hernandez; Masahiro Ohara; Morihito Okada; Agnes Viale; Adriana Heguy; Nicholas D Socci; Anna Sapino; Venkatraman E Seshan; Stephen Long; Giorgio Inghirami; Neal Rosen; Filippo G Giancotti
Journal:  Nat Cell Biol       Date:  2014-12-22       Impact factor: 28.824

6.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

7.  RhoJ modulates melanoma invasion by altering actin cytoskeletal dynamics.

Authors:  Hsiang Ho; Amelia Soto Hopkin; Rubina Kapadia; Priya Vasudeva; Jonathan Schilling; Anand K Ganesan
Journal:  Pigment Cell Melanoma Res       Date:  2013-01-07       Impact factor: 4.693

Review 8.  Rho GTPases: Anti- or pro-neoplastic targets?

Authors:  I Zandvakili; Y Lin; J C Morris; Y Zheng
Journal:  Oncogene       Date:  2016-12-19       Impact factor: 9.867

9.  The RhoJ-BAD signaling network: An Achilles' heel for BRAF mutant melanomas.

Authors:  Rolando Ruiz; Sohail Jahid; Melissa Harris; Diego M Marzese; Francisco Espitia; Priya Vasudeva; Chi-Fen Chen; Sebastien de Feraudy; Jie Wu; Daniel L Gillen; Tatiana B Krasieva; Bruce J Tromberg; William J Pavan; Dave S Hoon; Anand K Ganesan
Journal:  PLoS Genet       Date:  2017-07-28       Impact factor: 5.917

10.  A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis.

Authors:  Massimo Masiero; Filipa Costa Simões; Hee Dong Han; Cameron Snell; Tessa Peterkin; Esther Bridges; Lingegowda S Mangala; Sherry Yen-Yao Wu; Sunila Pradeep; Demin Li; Cheng Han; Heather Dalton; Gabriel Lopez-Berestein; Jurriaan B Tuynman; Neil Mortensen; Ji-Liang Li; Roger Patient; Anil K Sood; Alison H Banham; Adrian L Harris; Francesca M Buffa
Journal:  Cancer Cell       Date:  2013-07-18       Impact factor: 31.743

View more
  3 in total

1.  Overexpression of RhoV Promotes the Progression and EGFR-TKI Resistance of Lung Adenocarcinoma.

Authors:  Hongjin Chen; Ruixue Xia; Long Jiang; Yong Zhou; Haojun Xu; Weiwei Peng; Chengyun Yao; Guoren Zhou; Yijie Zhang; Hongping Xia; Yongsheng Wang
Journal:  Front Oncol       Date:  2021-03-09       Impact factor: 6.244

Review 2.  Rho GTPases in Retinal Vascular Diseases.

Authors:  Akiyoshi Uemura; Yoko Fukushima
Journal:  Int J Mol Sci       Date:  2021-04-01       Impact factor: 5.923

3.  RhoJ facilitates angiogenesis in glioblastoma via JNK/VEGFR2 mediated activation of PAK and ERK signaling pathways.

Authors:  Mei Wang; Chengfei Zhang; Qian Zheng; Zhijie Ma; Min Qi; Guangfu Di; Shizhang Ling; Haojun Xu; Bin Qi; Chengyun Yao; Hongping Xia; Xiaochun Jiang
Journal:  Int J Biol Sci       Date:  2022-01-01       Impact factor: 6.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.